Clarification on previous update! Study was for ovarian and breast cancer.
Lake Dallas, TX
Sep 29, 2013 — There was one clinical trial for four patient subtypes. Overall response rate 86%. This is stunning news. Great job, BioMarin - now give the drug to Andi! :-)